Hot and Ready
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kaufmann is Neurodevelopmental
Sabagh is Neurodegenerative.
Well Europe needs priming. With the absence of 3rd party review of a Misslingburger with cheese, I'd hope he spills the beans if we have any. The prize is the US FDA which we have NEVER heard DIRECT feedback on.
Yeah the big guys can't trust him because of his record. Not sure what Kun has been working on but I'd bet we submitted to FDA already.
I'll get beat up for that comment on this board but in his weird little mind I think that is what he really meant by his surprise the market commen last fall.
And say it's all BS? He is a much bigger player in the Neurology market then Missling. He should not have a leash or muzzle.
Whatever he says should be considered the Grail! But we won't hear it.
What year will Missling submit the NDA to the FDA.
2025,2026,2027,2028,2029,2030?
George is a joke. Mentioning his name encourages him. Let's keep it out of our mouths.
The flaw would be in the trial Dummy T.
Nitwit, if a trial fails to hit its predetermined endpoints it is a fail!
Your hero might think he can hire a biostatistician who is know for "fixing number" but by definition it did not hit its endpoints.
Your buddy has said so! It did not hit its endpoints. He wasted a year instead of NDAing Avatar
Idiot what exactly , specifically, was not true? Your pumping BS has people laughing AT you.
You must swim alot In the river called De Nile. But you probably do it very nicely. lol
By the way where is the 3rd party review? It's March.
Rett Trial Failed very Nicely, We still don't have a 3rd party review very nicely, We didn't submit to the EMA very nicely.
So All these FDA meetings and conversations and their results haven't been shared with shareholders. Only the EMA has been shared. Can one assume that the FDA told Missling to take a hike?
They are short. They've seen the CEO ef this up for some time. Market is made up of believers and non believers. Fritzy has fueled the non believers with his crap performance. No surprises. He still sucks.
"ve sumtimes like to surprise da merket" Stupid comment. They are making him eat his words.
Off a search on the internet. I don't make crap up. I could be wrong but I looked it up and saw that.
Portugal is 2 hours not 15 minutes
TGA and UK said change from phase 2 to phase 3. But we don't submit to them. We just sit and bleed.
WTF does he do all day? Looking at the presentation again it screams that this science need to be in the hands of a capable well funded BP
A 237 ?
I doubt Missling announces 3rd party Review on Monday. But that would get us to $12. If Sababbagh announces🤡 something great that could get us to $18
Meanwhile our CEO sits on Stat Sig results for 3 years
lol he has 136 followers. lol, how would you like to be on that board. lol
If Europe approves concurrently while FDA has been submitted we will be @$50.
You are a technical guy. Why do you care about events.
It's their trademark. Take it down to 52 week low and Gobble gobble.
looks like Fidelity to me
NIDAN I'm convince with both Missling at Cowen and Sabbagh at Lisbon we get news.
We need a European partner to put into the NDA docs. So that puts Pfizer, Merck, Sanofi, and a few more on notice. If you want the US you have to take Europe. Especially if you are based there.
I'm sure Ma has got feelers in the far east which might include Oz.
The big guys are gonna want Fritz out if it's the whole enchilada.
T WHAT COUNTRY HAS BEEN THE MOST FAVORABLE TO US, PAID FOR TRIALS, HAS LOTS OF FOLKS ON EXTENSION, HAS RWE?
Grimmer March 9th
RESULTS
The trial was successful, since the differences in the least-squares mean (LSM) change from baseline to 48
weeks between the blarcamesine and placebo groups were -1.783 [95% CI, -3.314 to -0.251]; (P = 0.0226)
for ADAS-Cog13, and -0.456 [95% CI, -0.831 to -0.080]; (P = 0.0175) for CDR-SB in patients with early AD.
In addition, validated biomarkers of amyloid beta pathology, plasma Aß42/40 ratio increased significantly (P
= 0.048), demonstrating strong anti-amyloid effects of blarcamesine in Alzheimer’s disease patients, while
MRI revealed significant reduction in brain volume loss, including whole brain (P = 0.0005), comparing
treatment to placebo.
Jesse did the numbers shared on the release seem good to you? TIA
No brainer to ask TGA for provisonal approval.
Another effing conference
lol wrong guy leading the charge.
Jefferson Starship If only you believe in miracles.........
LOL WE BOUGHT A COMPANY THAT WAS TO GET FDA APPROVAL FOR DRUG CANDIDATES FOR LARGE MARKETS.
NOT A NON REVENUE PRODUCING REASEARCH COMPANY.
WE NEED REVENUE AND LOTS OF IT.
I looked at your last 50 posts. WTF you need to get a life.
Who will pay for his new "precision medicine" (lol) trial
Not sure you have taken the time to take a breath. Blackrock took this country thru 2008.
Not that long ago we all talked about $1249 a share with 10% of market for Rett PDD and Alz.
$1249 x 6671000 shares is not something you allow a Putz to manage. They hire the best out of all major B schools as experts. They did not buy another 600000 shares for a failed Rett program.
Meanwhile, this deufuss has 100 million shares on the shelf and 10 million preferred to totally ef this up.
Respectfully Nidan, we all had a pretty good idea what we had and where we were going 8 years ago. Now because of poor execution we are on a row boat in the ocean waiting for a peer review. Pullease
I suggest you follow Elon Musks suggestion to his advertisers. I don't ask for your retort. You've become a one man BS machine.
You are guessing